Comparison of navelbine plus ifosfamide and cisplatin versus ifosfamide plus cisplatin in the treatment of advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 6, Issue 2, 2003, Pages 138-140

  Liao, Guoqing ^a   Wang, Hongmei ^a   Qu, Yimei ^a   Liu, Penghui ^a   Xie, Guoqing ^a   Dai, Haifeng ^a  

^a 309TH HOSPITAL OF PLA   (China)

Author keywords

Chemotherapy; Cisplatin; Ifosfamide; Navelbine; Non small cell lung cancer

Indexed keywords

CISPLATIN; IFOSFAMIDE; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEURITIS; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0037696317     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Brooks BJ, Gralla RJ. Cisplatin plus navelbine combination chemotherapy for the advanced non small cell lung cancer testing the efficacy of a regimen designed to reduce toxicity and increase dose-intensity. Proc ASCO, 1994,13: 348-351.
2. Le Chevalier T, Brisgand D, Douilland JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol, 1994,12(2): 360-367.